Zobrazeno 1 - 10
of 10
pro vyhledávání: '"J. J. Cancio Fanlo"'
Autor:
J. A. Valero Jaimes, A. De Diego Sola, N. Alcorta Lorenzo, C. A. Egües Dubuc, J. M. Belzunegui Otano, E. Uriarte Isacelaya, J. J. Cancio Fanlo, L. M. Lopez Dominguez, O. Maiz-Alonso
Publikováno v:
Annals of the Rheumatic Diseases. 81:1289.2-1289
BackgroundBaricitinib (BARI) is a selective and reversible oral Janus kinase (JAK) inhibitor for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients with inadequate response or intolerance to one or more antirheumat
Autor:
L. M. Lopez Dominguez, N. Alcorta Lorenzo, MA Aranguren Redondo, E. Uriarte Isacelaya, A. De Diego Sola, O. Maiz-Alonso, J. J. Cancio Fanlo, M.B. Irastorza Larburu, J. M. Belzunegui Otano, C. A. Egues
Publikováno v:
Annals of the Rheumatic Diseases. 80:1141-1142
Background:Biological disease modifying drugs (bDMARD) has allowed a targeted approach to rheumatoid arthritis (RA). Once sustained remission is achieved, the use of bDMARDs at lower doses than indicated in data sheets is considered (optimized treatm
Autor:
J. A. Valero Jaimes, A. C. Blanco Esteban, E. Uriarte Isacelaya, C.A. Egües Dubuc, A. De Diego Sola, N. Alcorta Lorenzo, O. Maiz-Alonso, J. J. Cancio Fanlo, J. M. Belzunegui Otano
Publikováno v:
Annals of the Rheumatic Diseases. 79:684.2-684
Background:Giant cell arteritis (GCA) presents with visual symptoms in approximately 37%1of patients at diagnosis. Patients with visual symptoms present, according to some series, lower levels of C-reactive protein (CRP) at diagnosis and associate le
Autor:
J. A. Valero Jaimes, A. De Diego, C.A. Egües Dubuc, J. Calvo, O. Maiz-Alonso, J. R. Furundarena Salsamendi, L. M. Lopez Dominguez, P. Cabrera Miranda, J. M. Belzunegui Otano, J. J. Cancio Fanlo, E. Uriarte Isacelaya, N. Alcorta Lorenzo
Publikováno v:
Annals of the Rheumatic Diseases. 79:837.2-838
Background:The Hemophagocytic Syndrome (HPS) is has been classified into 2 groups: primary and secondary. The secondary form is mainly associated with hemato-oncological diseases (HOD) and autoimmune diseases (AID). The present work aims to obtain cl
Autor:
P. Cabrera Miranda, O. Maiz-Alonso, A. De Diego, N. Alcorta Lorenzo, E. Uriarte Isacelaya, C.A. Egües Dubuc, J. M. Belzunegui Otano, J. J. Cancio Fanlo, J. A. Valero Jaimes, J. Calvo, L. M. Lopez Dominguez, J. R. Furundarena Salsamendi
Publikováno v:
Annals of the Rheumatic Diseases. 79:1214.2-1214
Background:The Hemophagocytic Syndrome (HPS) had a mortality rate between 20% and 90%. The mortality of HPS secondary to autoimmune diseases (AID) is lower than hemato-oncological diseases (HOD). In general, the HOD, thrombocytopenia, age, and a prol
Autor:
J. A. Valero Jaimes, O. Maiz-Alonso, C. A. Egues, A. De Diego Sola, E. Uriarte Isacelaya, J. M. Belzunegui Otano, N. Alcorta Lorenzo, L. M. Lopez Dominguez, J. J. Cancio Fanlo
Publikováno v:
Annals of the Rheumatic Diseases. 79:1893.2-1894
Background:Biological therapies have revolutionized the management of rheumatic diseases. This study analyzes the paradoxical autoimmune inflammatory manifestations that these therapies can induce. They are described as paradoxical because these are
Autor:
C.A. Egües Dubuc, I. Hernando Rubio, E. Uriarte Isacelaya, J. M. Belzunegui Otano, N. Errazquin Aguirre, C. Meneses Villalba, M. Uriarte Ecenarro, O. Maiz Alonso, V. Aldasoro Cáceres, M. Yague Asensio, J. J. Cancio Fanlo
Publikováno v:
Annals of the Rheumatic Diseases. 74:396.2-396
Background Secondary macrophage activation syndrome (MAS) is a group of diseases, especially due to autoimmune (AI) and hemato-oncology (HO). It would be interesting to find any clinical and analytics data to differentiate both etiologies. Objectives
Autor:
M. Yague Asensio, I. Hernando Rubio, I. Bañegil Espinoza, E. Uriarte Isacelaya, O. Maiz Alonso, C. Meneses Villalba, C.A. Egües Dubuc, M. Uriarte Ecenarro, N. Errazquin Aguirre, J. J. Cancio Fanlo, J. M. Belzunegui Otano
Publikováno v:
Annals of the Rheumatic Diseases. 73:1104.3-1105
Background The secondary macrophage activation syndrome (SMAS) is a group of diseases that include the: Autoimmune (AI), Hemato-Oncological (HO), Infectious (Inf) and Oncological (Onco). We make a review of the the cases presented in a our hospital.
Autor:
Belzunegui Otano J; Servicio de Reumatología, Hospital Nuestra Señora de Aránzazu, San Sebastián., López Domínguez L, Cancio Fanlo J
Publikováno v:
Revista clinica espanola [Rev Clin Esp] 1997 May; Vol. 197 (5), pp. 369-70.
Autor:
Belzunegui Otano J; Servicio de Reumatología, Hospital Nuestra Señora de Aránzazu, San Sebastián., Cancio Fanlo J, López Domínguez L, Figueroa Pedrosa M
Publikováno v:
Revista clinica espanola [Rev Clin Esp] 1997 May; Vol. 197 (5), pp. 365-6.